Arthroscopic evaluation of the synovial membrane and its relationship with histological changes and biomarkers in equine joint disease

Osteochondrosis in horses: An overview of genetic and other factors

Osteochondrosis (OC) is a frequent manifestation of developmental orthopaedic disease, and its severe clinical presentation is known as OC dissecans (OCD). OC is defined as a disruption of the endochondral ossification process in the epiphyseal cartilage, and this disease has been reported in different mammalian species, including humans, dogs, pigs, and horses. OCD is an important cause of lameness in sport horses and is a common cause of impaired orthopaedic potential, whose clinical signs may be of minimal magnitude or manifest as severe joint effusion or clinically noticeable lameness. The aetiology of OCD is unknown, although it has traditionally been considered to be multifactorial. In addition to genetic factors, associated factors include both non-genetic elements such as rapid growth, nutrition, trauma, anatomical conformation, and biomechanics. Since the prevalence of the disease varies greatly depending on the horse breed, from 13% in Swedish Warmblood to 53% in Lusitano breed, genetic factors have a great relevance in the appearance and development of OCD in horses. Many genetic modifications have been related, and the genes involved can be grouped into five clusters, related to fundamental functions for the correct development and regeneration of cartilage, such as collagen, laminin, cell signalling, matrix turnover, and transcriptional regulation. Changes in genes such as COL3A1, COL5A1, COL5A2, COL24A1, COL27A1 (collagen cluster), LAMB1 (laminin cluster), PTH, PHT receptors, and IHH (cell signalling), and genes encoding matrix metalloproteinases have been related to the occurrence and severity of diseases in different equine breeds. This review summarises the main factors associated with OC in horses, with particular emphasis on genetic factors.

Administration of sodium hyaluronate to adult horses prior to and immediately after exercise does not alter the range of motion in either the tarsus or metacarpophalangeal joints

Hyaluronic acid (HA), a glycosaminoglycan found in joint synovial fluid, is administered to horses as an anti-inflammatory with lubrication properties. This experiment examined the effects of HA administered before and shortly after an exercise test on metacarpophalangeal (MCP; fetlock) and tibiotarsal (hock) joint range of motion (ROM). Horses were injected intravenously (IV) with placebo (4 mL, saline) or HA (4 mL, 40 mg) 24 h before performing a standardized exercise test (SET) on a high-speed treadmill and again at 6-h post-SET. Passive fetlock flexion was measured at 4 and 24 h post-SET. Hock flexion and extension were measured at 24 h post-SET by videography and kinematic evaluation at the trot. Parameters of the SET were sufficient to cause peak lactate values of 6.6 ± 0.15 mM and a maximum heart rate of 203.6 ± 4.8 bpm. A minor gain (P = 0.08) in fetlock flexion prior to SET was observed in HA horses that were not retained at either 4 or 24 h post-SET. Hock flexion in both limbs was greater (P < 0.05) at 24 h post-SET, independent of treatment. Horses receiving HA exhibited reduced (P = 0.04) right hock extension. No differences in either right or left hock ROM were observed between control and HA-treated horses. From these results, it is concluded that IV HA injections surrounding an exercise stressor offer no substantive gains in either fetlock or hock ROM.